These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 19264368)
1. Induction chemotherapy with cisplatin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population. Airoldi M; Gabriele AM; Garzaro M; Raimondo L; Condello C; Beatrice F; Pecorari G; Giordano C Radiother Oncol; 2009 Jul; 92(1):105-10. PubMed ID: 19264368 [TBL] [Abstract][Full Text] [Related]
2. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Chua DT; Sham JS; Choy D; Lorvidhaya V; Sumitsawan Y; Thongprasert S; Vootiprux V; Cheirsilpa A; Azhar T; Reksodiputro AH Cancer; 1998 Dec; 83(11):2270-83. PubMed ID: 9840526 [TBL] [Abstract][Full Text] [Related]
3. Locoregionally advanced nasopharyngeal carcinoma: induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin: a phase II study. Ferrari D; Chiesa F; Codecà C; Calabrese L; Jereczek-Fossa BA; Alterio D; Fiore J; Luciani A; Floriani I; Orecchia R; Foa P Oncology; 2008; 74(3-4):158-66. PubMed ID: 18714164 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma. Al-Amro A; Al-Rajhi N; Khafaga Y; Memon M; Al-Hebshi A; El-Enbabi A; El-Husseiny G; Radawi A; Belal A; Allam A; El-Sebaie M Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):508-13. PubMed ID: 15890594 [TBL] [Abstract][Full Text] [Related]
5. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Azli N; Fandi A; Bachouchi M; Rahal M; Lianes P; Wibault P; Boussen H; Eschwege F; Armand JP; Cvitkovic E Cancer J Sci Am; 1995; 1(3):222-9. PubMed ID: 9166480 [TBL] [Abstract][Full Text] [Related]
6. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Chen Y; Liu MZ; Liang SB; Zong JF; Mao YP; Tang LL; Guo Y; Lin AH; Zeng XF; Ma J Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1356-64. PubMed ID: 18472356 [TBL] [Abstract][Full Text] [Related]
7. Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea. Park KH; Kim JS; Park Y; Seo HY; Park YJ; Choi IK; Oh SC; Seo JH; Kim CY; Jung KY; Shin SW; Kim YH; Kim JS; Lee NJ Cancer Chemother Pharmacol; 2010 Sep; 66(4):643-51. PubMed ID: 20033411 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Chua DT; Nicholls JM; Sham JS; Au GK Int J Radiat Oncol Biol Phys; 2004 May; 59(1):11-20. PubMed ID: 15093894 [TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study. Fountzilas G; Tolis C; Kalogera-Fountzila A; Karanikiotis C; Bai M; Misailidou D; Samantas E; Athanassiou E; Papamichael D; Tsekeris P; Catodritis N; Nicolaou A; Plataniotis G; Makatsoris T; Papakostas P; Zamboglou N; Daniilidis J Strahlenther Onkol; 2005 Apr; 181(4):223-30. PubMed ID: 15827691 [TBL] [Abstract][Full Text] [Related]
10. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. Chua DT; Ma J; Sham JS; Mai HQ; Choy DT; Hong MH; Lu TX; Min HQ J Clin Oncol; 2005 Feb; 23(6):1118-24. PubMed ID: 15657403 [TBL] [Abstract][Full Text] [Related]
11. Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates. Lin JC; Jan JS; Hsu CY; Jiang RS; Wang WY Br J Cancer; 2003 Jan; 88(2):187-94. PubMed ID: 12610501 [TBL] [Abstract][Full Text] [Related]
12. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials. Chua DT; Ma J; Sham JS; Mai HQ; Choy DT; Hong MH; Lu TX; Au GK; Min HQ Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1300-6. PubMed ID: 16750333 [TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy followed by alternating chemo-radiotherapy in non-endemic undifferentiated carcinoma of the nasopharynx: optimal compliance and promising 4-year results. Ponzanelli A; Vigo V; Marcenaro M; Bacigalupo A; Gatteschi B; Ravetti JL; Corvò R; Benasso M Oral Oncol; 2008 Aug; 44(8):767-74. PubMed ID: 18061519 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and feasibility of cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma. Demizu Y; Sasaki R; Soejima T; Maruta T; Okamoto Y; Yamada K; Yoden E; Ejima Y; Ota Y; Ishida H; Nibu K; Sugimura K Jpn J Clin Oncol; 2006 Oct; 36(10):620-5. PubMed ID: 16905756 [TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Kim K; Wu HG; Kim HJ; Sung MW; Kim KH; Lee SH; Heo DS; Kim HJ; Park CI Head Neck; 2009 Sep; 31(9):1121-8. PubMed ID: 19340863 [TBL] [Abstract][Full Text] [Related]
17. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. Wee J; Tan EH; Tai BC; Wong HB; Leong SS; Tan T; Chua ET; Yang E; Lee KM; Fong KW; Tan HS; Lee KS; Loong S; Sethi V; Chua EJ; Machin D J Clin Oncol; 2005 Sep; 23(27):6730-8. PubMed ID: 16170180 [TBL] [Abstract][Full Text] [Related]
18. [Concomitant chemo-radiotherapy for locoregionally advanced nasopharygeal carcinoma]. Tian Y; Chua DT; Sham JS Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):429-31. PubMed ID: 16188131 [TBL] [Abstract][Full Text] [Related]
19. Toxicity and feasibility analysis for cisplatin-based concomitant chemoradiotherapy in locally advanced nasopharyngeal carcinoma. Atasoy BM; Dane F; Yumuk PF; Akgün Z; Turhal NS; Abacioğlu U; Sengöz M J BUON; 2008; 13(1):43-50. PubMed ID: 18404785 [TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. Song CH; Wu HG; Heo DS; Kim KH; Sung MW; Park CI Laryngoscope; 2008 Apr; 118(4):663-70. PubMed ID: 18216741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]